Research & Innovation
China's breakthrough contributions to global pancreatic cancer treatment — publications, drug development, and international guideline alignment.
1. Publications & Conference Presentations
Chinese pancreatic cancer research teams are increasingly prominent at ESMO, AACR, and top-tier journals. Below are key publications and presentations.
Proteomic Biomarkers for Predicting Adjuvant Chemotherapy Benefit in PDAC
Prospective study of 1,171 postoperative PDAC patients. Proteomic profiling identified protein modules that predict adjuvant chemotherapy benefit, enabling personalized treatment selection.
PMID: 38287168 →Proteogenomic Characterization of Pancreatic Neuroendocrine Tumors — Clinically Relevant Subgroups
Proteogenomic analysis of non-functional pancreatic neuroendocrine tumors revealed clinically meaningful molecular subtypes, enabling more precise treatment strategies.
PMID: 40185092 →Cell-Free DNA Fragmentomics Model for Early Detection of Pancreatic Cancer
Development and validation of a cfDNA fragmentomics-based early detection model for pancreatic cancer — a non-invasive blood test with potential for population-level screening.
PMID: 40311105 →Psychological Stress Promotes Pancreatic Cancer via Extracellular Vesicle RNA Transfer
Landmark discovery: psychological stress induces ALKBH5 deficiency, promoting tumor innervation and pancreatic cancer progression through extracellular vesicle RNA transfer — revealing a stress-tumor interaction mechanism.
PMID: 40419796 →Single-Cell & Spatial Transcriptomics of Neural Invasion in Pancreatic Cancer
Integrated single-cell and spatial transcriptomics uncovered distinct cellular subtypes involved in neural invasion — a key mechanism of pancreatic cancer metastasis and pain.
PMID: 40680743 →SPP1 Maintains Mesenchymal Cell Fate in Pancreatic Cancer
Identified SPP1 as a critical factor maintaining mesenchymal cell fate in pancreatic cancer — a potential new therapeutic target for disrupting tumor stroma interactions.
PMID: 40993391 →Robotic vs Open Whipple: 10-Year Comparative Study (450 vs 634 Cases)
Landmark 10-year comparison demonstrating comparable oncologic outcomes with robotic approach showing advantages in blood loss and recovery time.
Pancreatic Cancer Systemic Therapy: Asia-Pacific Expert Consensus
First Asia-Pacific consensus on pancreatic cancer systemic therapy. Prof. Shen was the only Chinese expert on the core writing committee, adapting global standards to Asian patients.
PMID: 41067164 →JS107: CLDN18.2-Targeting ADC for Pancreatic Cancer & Solid Tumors
Phase I study of JS107, an antibody-drug conjugate targeting CLDN18.2, as monotherapy or combination for advanced solid tumors including pancreatic cancer (AACR 2025, CT010).
World's First KRAS G12V-Targeted TCR-T Cell Gene Therapy for Pancreatic Cancer
First-in-human Phase I/II trial of TCR-T cell gene therapy targeting KRAS G12V mutation in 5 recurrent pancreatic cancer patients. A landmark in adoptive cell therapy for solid tumors.
PMID: 41814655 →Fudan Cancer Center: 35 Papers with Impact Factor ≥ 20
In 2025 alone, FUSCC published 35 papers in journals with IF ≥ 20, including 3 papers in BMJ and Nature main editions. The institution's clinical research changed international guidelines 17 times in a single year.
Multiple AACR Presentations on KRAS-targeted Therapies and Tumor Microenvironment
Chinese teams presented multiple abstracts at AACR 2024-2025 on KRAS G12D inhibitor clinical data, pancreatic cancer tumor microenvironment characterization, and novel combination strategies.
AACR →2. Drug Development Breakthroughs
China is at the forefront of developing next-generation pancreatic cancer therapies, particularly KRAS inhibitors and mRNA cancer vaccines.
KRAS Inhibitors
GFH375 (VS-7375)
GenFleet Therapeutics (劲方医药) · Licensed to Verastem OncologyOral, highly selective KRAS G12D inhibitor — dual-targeting both "ON" (GTP-bound) and "OFF" (GDP-bound) states. ESMO 2025 data showed striking efficacy in previously treated KRAS G12D patients.
KRAS G12D is the most common KRAS mutation in pancreatic cancer (~40% of cases). GFH375's ORR of 40.7% in a heavily pretreated population is a significant advance.
HRS-4642
Jiangsu Hengrui Pharmaceuticals (江苏恒瑞医药)The world's first KRAS G12D inhibitor to receive Breakthrough Therapy Designation (Feb 2026). Now in a Phase III pivotal trial (NCT07232875): HRS-4642 + AG chemotherapy vs AG alone as first-line treatment for advanced KRAS G12D-mutant pancreatic cancer.
HRS-4642 is only the second KRAS G12D inhibitor globally to reach Phase III, positioning Hengrui at the cutting edge of this target.
| Drug | Developer | Mechanism | Stage | Key Data |
|---|---|---|---|---|
| HRS-4642 | Hengrui (China) | KRAS G12D selective | Phase III | Breakthrough Therapy; first-line combo |
| GFH375 | GenFleet (China) | KRAS G12D selective (ON+OFF) | Phase I/II | ORR 40.7%, DCR 96.7% |
| RMC6236 | Revolution Medicines (US) | Pan-RAS (ON-state) | Phase III (success) | Covers >90% PDAC mutations; FDA filing planned |
RMC6236 vs Chinese G12D Inhibitors — Key Difference
RMC6236 is a pan-RAS inhibitor covering all major RAS mutations (G12D, G12V, G12R, etc.) — applicable to >90% of pancreatic cancers. HRS-4642 and GFH375 are G12D-selective — targeting the ~40% of pancreatic cancers with this specific mutation. For G12D patients specifically, Chinese inhibitors may offer superior target selectivity and a cleaner safety profile.
mRNA Cancer Vaccines
XP-004 — Personalized Pancreatic Cancer Vaccine
Ruijin Hospital (瑞金医院) · Pancreatic Disease CenterPersonalized mRNA vaccine encoding tumor neoantigens. Currently in a clinical trial (NCT06496373) combined with PD-1 inhibitor as adjuvant therapy for pancreatic cancer patients post-surgery who cannot tolerate standard chemotherapy.
Ruijin's vaccine development is backed by their massive clinical database of 30,000+ pancreatic cancer cases, providing a unique advantage in identifying optimal neoantigen targets.
ABO2102 — Universal KRAS-targeting mRNA Vaccine
Abogen Biosciences (艾博生物)mRNA vaccine targeting 5 common KRAS mutations. Received NMPA IND approval in China and US FDA clinical trial authorization (Aug 2025). Designed as monotherapy and combination with toripalimab (anti-PD-1) for KRAS-mutant advanced pancreatic cancer.
| Vaccine | Developer | Target | Stage | Key Data |
|---|---|---|---|---|
| ELI-002 | Eli Lilly / Amphivena (US) | mKRAS (7 mutations) | Phase II | 98.9% T-cell induction; 145x T-cell expansion (AMPLIFY-7P) |
| XP-004 | Ruijin Hospital (China) | Personalized neoantigens | Phase I | 30K+ case database for neoantigen selection |
| ABO2102 | Abogen (China) | 5 common KRAS mutations | Phase I | Dual IND: China + US (Aug 2025) |
Why this matters for patients
China's clinical trial infrastructure means access to these cutting-edge therapies is often free of charge for eligible patients. For KRAS-mutant pancreatic cancer patients who have exhausted standard options, enrolling in a Chinese clinical trial may provide access to tomorrow's medicine today — without the $150K+ cost of novel targeted therapies in the US.
3. Global Treatment Guidelines
Pancreatic cancer treatment should follow internationally recognized guidelines. Below are the latest NCCN guidelines for both clinicians and patients. China's top hospitals align closely with these standards while also contributing new evidence that shapes future editions.
NCCN Clinical Practice Guidelines
Professional guidelines for oncologists. Pancreatic adenocarcinoma — screening, diagnosis, staging, and treatment algorithms.
View on NCCN.org →NCCN Patient Guidelines
Patient-friendly version. Explains treatment options, side effects, and questions to ask your doctor. 72-page comprehensive guide.
Download PDF (1.7 MB) ↓Also available on NCCN.org →
China's Role in Guideline Development
Prof. Shen Baiyong (Ruijin Hospital) was the only Chinese expert on the ESMO Asia-Pacific Pancreatic Cancer Consensus writing committee. Fudan Cancer Center's research changed international clinical guidelines 17 times in 2025 alone. China is no longer just following global standards — it is helping to write them.
Disclaimer: This page is for informational purposes only. Drug development timelines and clinical trial data are based on publicly available information and may change. NCCN guidelines are copyrighted by NCCN and provided here for patient convenience — always refer to the official NCCN website for the latest version. This page does not constitute medical advice. Consult your treating physician before making treatment decisions.